Highlights

  • NOVONIX amended its PowerCo Supply agreement and continued synthetic graphite qualification work.
  • Archer announced a quantum commercial pilot and a later quantum Leadership appointment.
  • 4DS completed the Jenesys acquisition, adding edge-AI software alongside its ReRAM program.
  • Technical milestones do not automatically establish future production volumes or dependable commercial revenue.

Some of the market’s smallest technology stocks are working on problems that require extensive testing before the Business model becomes predictable. NOVONIX Limited (ASX:NVX), Archer Materials Limited (ASX:AXE) and 4DS Memory Limited (ASX:4DS) are pursuing battery materials, quantum technology and advanced computing, respectively. Their 13 November 2026 quoted prices were AUD 0.081, AUD 0.170 and AUD 0.006, with no reported percentage changes.

Graphite Qualification Shapes Battery Plans

NOVONIX is developing synthetic graphite anode material for batteries used in electric vehicles and stationary energy storage. In October 2026, it announced amendments to its PowerCo supply arrangement, while customer feedback disclosed in September marked another stage in the qualification process. It also achieved ISO 9001:2015 quality-management certification in October and issued its September-quarter activities update later that month. Certification and amended commercial terms advance the company’s operating framework, but they should not be confused with completed mass production or realised future supply volumes. Its development path depends on material qualification, Manufacturing execution, funding and Demand from battery customers. Investors watching those milestones should distinguish conditional supply arrangements from actual deliveries.

Quantum Development Moves Toward Pilots

Archer Materials has been progressing quantum research alongside a separate biosensor development stream. Its announcements included a quantum commercial pilot in September and a leadership appointment focused on quantum activity in early November. The company also released its September-quarter report in late October. A pilot can give potential customers and engineers a way to evaluate technology in a real operating setting, but outcomes depend on technical milestones and eventual adoption. That is a different commercial phase from recurring software Revenue or established manufacturing sales. Archer’s 13 November quoted share price was AUD 0.170, unchanged on the day, while its next disclosed pilot outcomes and program expenditure will provide a clearer picture of progress.

Memory Research Adds an Edge AI Business

4DS completed its Acquisition of Jenesys on 9 October after Shareholder approval, adding edge-AI software for autonomous systems alongside its resistive-memory technology. The company reported AUD 6.6 mn in cash at September-end and has described an analogue in-memory computing research roadmap for its ReRAM program. The acquisition broadens the company’s technological interests, but the software operation and memory research have different Maturity and cash-flow characteristics. At AUD 0.006 on 13 November, the stock showed no daily change in the stated figures. The key issue is how the enlarged portfolio develops commercially while the company manages research commitments and available capital.

Research Milestones and Commercial Contracts

The three stocks are frequently discussed under an innovation umbrella, but their technology and commercial challenges are not the same. NOVONIX must qualify a manufactured material to the specifications of battery customers and then meet supply commitments. Archer’s pilot-based work seeks to establish whether quantum technology can operate effectively in selected practical settings. 4DS is combining memory research with a newly acquired software business, adding integration questions to its technology roadmap. A customer evaluation, a laboratory milestone and an acquisition completion each signal a different stage of progress. It would be misleading to treat them as equivalent to contracted revenue or near-term manufacturing output. Cash requirements and execution timelines remain central to future disclosures.

What Comes Next?

Battery qualification, quantum pilots and memory research carry different timelines and Capital requirements. For all three companies, completed technical milestones are useful evidence of work accomplished, while customer commitments, manufacturing readiness and cash resources will be the stronger tests of future commercial progress.